Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational bioregulator schedule
10 mcg daily in weeks 1-2, 20 mcg in weeks 3-4, 50 mcg in weeks 5-6 and 100-150 mcg in weeks 7-16
No matched controlled human study validates these very small quantities or the proposed route. The schedule is retained only as low-confidence provenance.
View sourceEvidence summary
A peptide bioregulator marketed for ovarian and endocrine claims. Robust indexed human evidence is insufficient to establish a reproducible protocol.
Protocol basis
The page records the sparse evidence base and therefore provides no invented administration schedule.
What remains uncertain
Identity, human exposure, fertility effects, interactions, safety and controlled efficacy are unknown.
Warnings and contraindications
No adequate controlled human regimen was identified in major indexed literature.
Reproductive and endocrine claims require specialist clinical evidence.
Vendor schedules cannot substitute for matched formulation and outcome data.